Altimmune Inc
Research Altimmune Inc (ALT) on Bullrun: market cap USD 507.58M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 507.58M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 22.83M
- Free cash flow-USD 24.25M
Valuation Snapshot
latest market cap is USD 507.58M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 41.00K | -USD 88.09M | -USD 67.55M | n/a | -1 | USD 43.76M | USD 34.29M | USD 224.89M |
| FY2024 | USD 20.00K | -USD 95.06M | -USD 79.85M | n/a | -1.34 | USD 36.93M | USD 1.68M | USD 123.51M |
| FY2023 | USD 426.00K | -USD 88.45M | -USD 75.86M | n/a | -1.66 | USD 135.12M | USD 671.00K | USD 194.10M |
| FY2022 | -USD 68.00K | -USD 84.71M | -USD 62.71M | n/a | -1.81 | USD 111.10M | USD 4.58M | USD 185.29M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 507.58M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 400.29M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 521.66M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 604.45M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 808.67M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 375.50M | n/a | n/a | n/a |
About Altimmune Inc
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Altimmune Inc's market cap?
Altimmune Inc's market capitalization is USD 507.58M.
What does Altimmune Inc do?
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.